Pharmacokinetic study of HP-5120

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031240331

Enrollment

112

Registered

2024-09-11

Start date

2024-10-17

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy adult males and females

Interventions

[Single ascending dose in healthy adult Japanese males and females] In Cohort 1, a single dose of HP-5120 Dose 1 or placebo will be administered. In Cohort 2, a single dose of HP-5120 Dose 2 or placeb

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Healthy adult Japanese males and females aged 18 or older and younger than 45 years - Subjects weighing 40 kg or more

Exclusion criteria

Exclusion criteria: - Subjects with or with a history of serious cardiovascular, renal, hepatic, gastrointestinal, endocrine, neuropsychiatric, dermatological, metabolic, or immunological disease - Subjects who received any drug within 1 week prior to administration of the investigational product - Subjects who took any drug considered to affect drug metabolism within 4 weeks prior to administration of the investigational product

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics, Safety	—

Contacts

Public ContactContact for Clinical Trial Information Clinical Development Department

Hisamitsu Pharmaceutical Co., Inc.

shikenjoho@hisamitsu.co.jp+81-3-5293-1734

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026